Cencora

(New York Stock Exchange)
Back to all articles
Bullish +65

Cencora raises earnings guidance: 13 analysts rate Cencora stock Buy

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Cencora reported fiscal Q3 2026 adjusted earnings per share of USD 4.48, beating the consensus estimate of USD 4.37 by 2.52%.

πŸ’° Total revenue reached USD 84.75 billion, marking a 5.10% year-over-year increase driven by strong volume growth.

πŸš€ Adjusted operating income surged 17.00% to USD 1.24 billion, reflecting improved operational efficiency and execution.

πŸ’Š U.S. Healthcare Solutions revenue hit USD 74.90 billion, up 4.90%, with specialty products like GLP-1 medicines fueling growth.

πŸ“ˆ The company raised its fiscal 2026 adjusted earnings guidance to USD 17.75-17.95 per share from the prior range of USD 17.70-17.90.

πŸ”­ Forward guidance projects fiscal 2026 revenue growth between 4.00% and 6.00% with adjusted operating income growing 13.00-14.00%.

πŸ“Š Analyst consensus remains bullish with 13 Buy ratings versus 3 Hold ratings, setting an average price target of USD 370.85.

⚠️ Net interest expense increased sharply by 72.00% to USD 140.70 million, adding pressure to overall profitability metrics.

πŸ“‰ The company acknowledged the loss of an oncology customer as a counterweight to its otherwise strong financial performance.

πŸ“… Upcoming fiscal fourth-quarter results scheduled for November 4, 2026, will test whether the raised guidance can be sustained.

Bullish Signals
  • Cencora beat Q3 earnings estimates with adjusted EPS of USD 4.48 versus a consensus of USD 4.37, demonstrating strong execution.
  • Adjusted operating income grew robustly by 17.00% to USD 1.24 billion, highlighting improved operational leverage.
  • The U.S. Healthcare Solutions segment drove revenue growth of 4.90% to USD 74.90 billion, bolstered by high-volume specialty products.
  • Management raised full-year fiscal 2026 adjusted earnings guidance to USD 17.75-17.95 per share, signaling confidence in future performance.
  • Analyst sentiment is strongly positive with a Moderate Buy consensus and an average price target of USD 370.85.
Risk Factors
  • Net interest expense spiked by 72.00% to USD 140.70 million, which partially offset the gains in operating income.
  • The company noted the loss of an oncology customer as a specific headwind affecting its revenue mix.
Full Analysis
Cencora Inc. reported a strong fiscal third quarter in 2026, with adjusted earnings per share of USD 4.48 beating the consensus estimate of USD 4.37 by 2.52%. The company also posted GAAP earnings per share of USD 3.94 and total revenue of USD 84.75 billion, representing a 5.10% year-over-year increase. Adjusted operating income rose significantly by 17.00% to USD 1.24 billion, driven largely by growth in its U.S. Healthcare Solutions segment. The core driver of this performance was the U.S. Healthcare Solutions division, which generated USD 74.90 billion in revenue, up 4.90% year over year. This segment's operating income increased by 15.90% to USD 966.20 million, supported specifically by volume growth in specialty products, including high-demand GLP-1 medicines. Despite a notable increase in net interest expense of 72.00% to USD 140.70 million and the loss of an oncology customer, the company demonstrated robust execution. Following these results, Cencora raised its fiscal 2026 adjusted earnings guidance to a range of USD 17.75-17.95 per share, up from the previous forecast of USD 17.70-17.90. The company also provided forward-looking revenue growth expectations of 4.00-6.00% and adjusted operating income growth of 13.00-14.00% for the full year. Analyst sentiment remains positive, with 13 analysts maintaining Buy ratings and an average price target of USD 370.85.